IGFBP-2 總 ELISA-IGFBP-2 Total ELISA代理/參數(shù)/廠家-ELISA試劑盒-艾美捷科技有限公司

PRODUCT CENTER

ELISA試劑盒

產(chǎn)品中心

當(dāng)前位置：首頁(yè) > 產(chǎn)品中心 > 免疫學(xué)產(chǎn)品 > ELISA試劑盒

中文名稱: IGFBP-2 總 ELISA

英文名字: IGFBP-2 Total ELISA

供應(yīng)商: Ansh Labs

產(chǎn)品貨號(hào): AL-140

產(chǎn)品報(bào)價(jià): ￥詢價(jià)/96wellmicrotiter

產(chǎn)品說明書: 點(diǎn)擊查看

購(gòu)買方式: 90%產(chǎn)品中國(guó)有現(xiàn)貨庫(kù)存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868

產(chǎn)品新聞

背景資料: IGFBP-2 is an unglycosylated polypetide of 31.3 kDa and is one of the six circulating proteins that bind insulin-like growth factor (IGF)-I and -II with high affinity. Cleavage of signal peptide from the precursor protein generates the 31 kDa mature IGFBP-2, which consists of N- and C-terminal cysteine rich regions (1,2). Both N- and C-terminal regions of IGFBP-2 bind IGF-I and IGF-II preventing their interaction with IGF-1 receptor (2). IGFBP-2 mainly exists in non-glycosylated and non-phosphorylated form (3,4).
n
nIGFBP-2 is a widely expressed protein with functions in bone and skeletal muscle development, and regulation of body growth and composition (5). Pure congenic IGFBP2 -/- mice show gender and bone compartment-specific phenotypes (6). IGFBP-2 overexpression mice have reduced body weight suggesting a role in postnatal growth by potentially regulating IGF-I bioavailability (7).
n
nIGFBP-2 levels in circulation are influenced under different metabolism and malignant states (5). IGFBP-2 levels are high in cord serum from term infants, in contrast plasma IGFBP-2 levels in adults are lower (8). IGFBP-2 levels in adults are subjected to minimal daily fluctuations suggesting that postprandial changes in glucose and insulin levels do not influence IGFBP-2 levels (8). Compared to normal adults, IGFBP-2 levels are elevated in hypopituitary adults suggesting regulation by growth hormone (8). Extreme physical exercise results in elevated serum IGFBP-2 levels in men and women (5). Circulating IGFBP-2 levels are high in anorexia nervosa patients and suppressed in obesity and Type 2 diabetes (5). Overexpression of IGFBP-2 protects against obesity and diabetes by inhibiting adipogenesis and modulating insulin sensitivity (9,10). In contrast to Type 2 diabetes, IGFBP-2 levels are increased in Type 1 diabetes suggesting regulation by insulin sensitivity (11). Low postpartum IGFBP-2 levels are associated with the development of Type 2 diabetes in women with history of gestational diabetes mellitus (12).
n
nIGFBP-2 levels are also altered in intra-uterine growth retardation (IUGR) and small for gestational age (SGA) cases. In IUGR cord serum levels of IGFBP-2 are elevated and levels are low in pre-pubertal and pubertal SGA subjects (5). IGFBP-2 role in cancer progression is indicated by elevated levels in several malignancies like prostate, ovarian, breast and gastric cancer (5). In colon cancer IGFBP-2 levels are elevated in plasma and is associated with increased risk of mortality (13). Recently, IGFBP-2 was identified as an early stage biomarker in invasive ductal adenocarcinoma of pancreas (14) and elevated serum IGFBP-2 levels were reported in idiopathic pulmonary fibrosis and Lupus nephritis patients (15,16). Circulating levels of IGFBP-2 may be an important biomarker of different metabolic and malignant states.
n
nReferences:
n1. Binkert C, Landwehr J, Mary JL, Schwander J, Heinrich G. Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2). EMBO J 1989;8:2497–502.
n2. Galea CA, Mobli M, McNeil KA, Mulhern TD, Wallace JC, King GF, et al. Insulinlike growth factor binding protein-2: NMR analysis and structural characterization of the N-terminal domain. Biochimie 2012;94:608–16.
n3. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824–54.
n4. Coverley JA, Baxter RC. Phosphorylation of insulin-like growth factor binding proteins. Mol Cell Endocrinol 1997;128:1–5
n5. Russo VC, Azar WJ, Yau SW, Sabin MA, Werther GA. IGFBP-2: The dark horse in metabolism and cancer. Cytokine Growth Factor Rev. 2015 Jun;26(3):329-46
n6. DeMambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, et al. Gender-specific changes in bone turnover and skeletal architecture in IGFBP-2-null mice. Endocrinology 2008;149:2051–61.
n7. Hoeflich A, Wu M, Mohan S, Foll J, Wanke R, Froehlich T, et al. Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain. Endocrinology 1999;140:5488–96.
n8. Clemmons DR, Snyder DK, Busby Jr WH. Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects. J Clin Endocrinol Metab 1991;73:727–33.
n9. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M, et al. IGFbinding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007;56:285–94.
n10. Hedbacker K, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab 2010;11:11–22.
n11. Frystyk J, Skjaerbaek C, Vestbo E, Fisker S, Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab Res Rev 1999;15:314–22.
n12. Lappas M, Jinks D, Shub A, Willcox JC, Georgiou HM, Permezel M. Postpartum IGF-I and IGFBP-2 levels are prospectively associated with the development of type 2 diabetes in women with previous gestational diabetes mellitus. Diabetes Metab. 2016.
n13. Liou J-M, Shun C-T, Liang J-T, Chiu H-M, Chen M-J, Chen CC, et al. Plasma insulin- like growth factor-binding protein-2 levels as diagnostic and prognostic bio- marker of colorectal cancer. J Clin Endocrinol Metab 2010;95:1717–20.
n14. Yoneyama T, Ohtsuki S, Honda K et al. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. PLoS One. 2016;11(8)
n15. Guiot J, Bondue B, Henket M, Corhay JL, Louis R. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med. 2016;16(1):86.
n16. Ding H, Kharboutli M, Saxena R, Wu T. Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis. Clin Exp Immunol. 2016 Apr;184(1):11
n17. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
n18. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence Bulletin 13 - Explosive Azide Hazard. Available http:// www.cdc.gov/niosh.
n19. DOT
n20. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.

產(chǎn)品描述: The IGFBP-2 enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGFBP-2 in human serum and other biological fluids.

產(chǎn)品特點(diǎn)

保存建議: Store at 2 to 8°C until expiration date.

其他: Ansh labs是開發(fā)和生產(chǎn)免疫檢測(cè)試劑盒和定制生物技術(shù)檢測(cè)產(chǎn)領(lǐng)創(chuàng)者，總部位于美國(guó)休斯敦，公司產(chǎn)品遍及全球80多個(gè)國(guó)家。公司于2011年成立，核心團(tuán)隊(duì)來自于Diagnostic system laboratory，專注于女性健康和激素檢測(cè)領(lǐng)域近40年，擁有全球領(lǐng)先的核心技術(shù)，以及多年經(jīng)驗(yàn)生物技術(shù)研發(fā)經(jīng)驗(yàn)的科學(xué)家團(tuán)隊(duì)，產(chǎn)品覆蓋生殖健康，高危妊娠，腫瘤，糖尿病等多個(gè)疾病領(lǐng)域，圍繞最新的免疫分析技術(shù)，多種蛋白和單克隆抗體，如AMH，BMP-15, Follistatin, GDF-9, IGF-I, IGF-II, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, Inhibin Alpha, Inhibin ?A, Inhibin ?B, MBP, PAPP-A, PAPP-A2 and Vitamin D.等幾十余種試劑產(chǎn)品，也同時(shí)涵蓋小鼠，大鼠，狗，羊，牛等靈長(zhǎng)類多個(gè)物種的獨(dú)特的物種特異性的試劑。 Ansh labs 坐落于美國(guó)德克薩斯州，是目前世界上唯一能提供TGF-β超家族所有成員的檢測(cè)公司，也是最早專注激素類產(chǎn)品研究和新型免疫檢測(cè)技術(shù)的先驅(qū)者。優(yōu)勢(shì)產(chǎn)品涉及TGF-β super family、AMH/抑制素B(human/animal)、full panel IGFs、以及最完整的胰高血糖素系列。